AstraZeneca (AZN)

Sector:

Pharma and Biotech

Index:

FTSE 100

10,436.00p
   
  • Change Today:
      14.00p
  • 52 Week High: 13,276.00
  • 52 Week Low: 9,501.00
  • Currency: UK Pounds
  • Shares Issued: 1,550.32m
  • Volume: 754,278
  • Market Cap: £161,791m
  • RiskGrade: 123
  • Beta: 0.87

AstraZeneca Overview

A world-leading pharmaceutical group, AstraZeneca was created in 1999 via the merger of Sweden's Astra and the UK's Zeneca, which had been demerged from chemicals group ICI in 1993. About half of its total sales are generated from the US, with over a third of revenues coming from its gastrointestinal treatments such as Prilosec (Losec) and Nexium.

1 Day Chart (24-12-2024)

1 Day Chart

6 Month Chart

6 Month Chart
Barclays logo

Digital Look Charts Sponsored by Barclays Stockbrokers

AstraZeneca Financials

Latest F'cast
Div Yield 2.2% 0.0%
Div Cover 1.3 2.6
Op Mrgn 17.9% 29.7%
ROCE 62.6%  
Latest F'cast
P/E 34.1 16.4
PEG 0.4 0.2
Pr/Revenue 4.4 3.1
Pr/Book 5.2  
Latest F'cast
Revenue 3.3% -7.7%
PBT 175.8% 82.1%
EPS 81.1% 108.4%
DPS n/a -31.6%

AstraZeneca Fundamentals

Year Ending Revenue ($m) Pre-tax ($m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-19 24,384.00 1,548.00 103.00¢ 92.6 n/a -39% 280.00¢ 2.9%
31-Dec-20 26,617.00 3,916.00 244.00¢ 37.6 0.3 +137% 280.00¢ 3.0%
31-Dec-21 37,417.00 (265.00) 8.00¢ 1,360.5 n/a -97% 287.00¢ 2.6%
31-Dec-22 44,351.00 2,501.00 212.00¢ 66.4 0.0 +2,550% 290.00¢ 2.1%
31-Dec-23 45,811.00 6,899.00 384.00¢ 34.6 0.4 +81% 290.00¢ 2.2%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

AstraZeneca Forecasts

Year Ending Revenue (£m) Pre-tax (£m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-24 53,022.99 15,757.26 636.40p 16.4 0.2 +108% 248.63p 0.0%
31-Dec-25 56,922.71 17,789.84 727.59p 14.3 1.0 +14% 260.74p 0.0%
31-Dec-26 60,189.54 19,820.34 831.30p 12.6 0.9 +14% 274.54p 0.0%

Copyright © 2024 FactSet Research Systems Inc. All rights reserved.

AstraZeneca Company Announcements

Dato-DXd NSQ NSCLC application withdrawn in EU 24-Dec-2024 07:00 RNS
Tagrisso approved in EU based on LAURA trial 23-Dec-2024 07:00 RNS
Directorate Change 16-Dec-2024 07:00 RNS

AstraZeneca ShareCast News

AstraZeneca pulls EU application for cancer drug 24-Dec-2024 ShareCast
AstraZeneca lung cancer drug Tagrisso approved b... 23-Dec-2024 ShareCast
AstraZeneca cancer drug secures US approval 05-Dec-2024 ShareCast

AstraZeneca Top Newspaper Links

Fighting Frenchman shows us how as he ensures As... 30-Dec-2014 Daily Mail
Exclusive: UK firms vie for share of £170bn in A... 08-Dec-2014 The Independent
MARKET REPORT: Ariad on the up amid growing spec... 04-Dec-2014 Daily Mail

Latest AstraZeneca Director Deals

No deals were found in the last 28 days.

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

Note 3: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 4: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 5: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 6: Forecast figures based on normalised accounts.

 

AstraZeneca Market Data

Currency UK Pounds
Share Price 10,436.00p
Change Today 14.00p
% Change 0.13 %
52 Week High 13,276.00
52 Week Low 9,501.00
Volume 754,278
Shares Issued 1,550.32m
Market Cap £161,791m
Beta 0.87
RiskGrade 123

AstraZeneca Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
89.55% below the market average89.55% below the market average89.55% below the market average89.55% below the market average89.55% below the market average
84% below the sector average84% below the sector average84% below the sector average84% below the sector average84% below the sector average
Price Trend
21.8% below the market average21.8% below the market average21.8% below the market average21.8% below the market average21.8% below the market average
55.10% above the sector average55.10% above the sector average55.10% above the sector average55.10% above the sector average55.10% above the sector average
Income
82.38% below the market average82.38% below the market average82.38% below the market average82.38% below the market average82.38% below the market average
42.86% below the sector average42.86% below the sector average42.86% below the sector average42.86% below the sector average42.86% below the sector average
Growth
89.65% above the market average89.65% above the market average89.65% above the market average89.65% above the market average89.65% above the market average
93.94% above the sector average93.94% above the sector average93.94% above the sector average93.94% above the sector average93.94% above the sector average

What The Brokers Say

Strong Buy 9
Buy 14
Neutral 6
Sell 0
Strong Sell 0
Total 29
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

AstraZeneca Dividends

  Latest Previous
  1st Interim 2nd Interim
Ex-Div 08-Aug-24 22-Feb-24
Paid 09-Sep-24 25-Mar-24
Amount 100.00¢ 197.00¢

Trades for 24-Dec-2024

Time Volume / Share Price
10:58 272,331 @ 10,478.00p
12:54 46,372 @ 10,478.00p
12:54 46,372 @ 10,478.00p
12:35 191,128 @ 10,436.00p
12:35 324 @ 10,436.00p

AstraZeneca Key Personnel

Chair Michel Demare

Top of Page